SMAD4 and cancer: In conclusion, SMAD4 homozygous deletion favors the constitutive activation of ERK, the EGF-induced activation of NF-κB and PI3K/AKT, and the EGF-induced inhibition of Wnt/β-catenin pathways, which are critical to cancer proliferation and metastases.